IPCA Q1 FY27: consolidated PAT +72% YoY to ₹402 Cr as margins expand, revenue +21%

Ipca's Q1 FY27 print is unambiguously strong on a year-on-year basis: consolidated PAT of ₹401.89 Cr rose 72% YoY (the company's own release cites 80% using a pre-minority-interest base of ₹422.81 Cr), on consolidated revenue of ₹2,788.10 Cr, up 21% YoY and 16.7% QoQ. Standalone PAT was ₹373.29 Cr, up 42% YoY, on revenue of ₹2,119.24 Cr, also up 21%. Neither period carries an exceptional item this quarter, making it a clean read against Q4 FY26, which had absorbed a ₹45.82 Cr (consolidated) labour-code exceptional charge.

The margin story is the real driver: consolidated EBITDA margin (before forex and other income) expanded to 22.88% from 18.39% a year ago, and standalone margin to 26.27% from 23.82%. Consolidated total expenses grew only ~11.5% (₹2,241.28 Cr vs ₹2,011.00 Cr) against 21% revenue growth — clear operating leverage, not a forex artifact, since the EBITDA metric already excludes forex (which itself swung favorable: a ₹31.57 Cr consolidated gain versus an ₹8.16 Cr loss a year ago). Mix also helped: institutional export formulations jumped 107% YoY to ₹119.75 Cr, generics exports rose 27% to ₹340.02 Cr and API exports grew 33% to ₹332.35 Cr — export income overall (+34% standalone) comfortably outpaced domestic formulations (+13%).

The stock went into the print at ₹1,797, down 4.3% over the past month of trading.

For context: this is the highest quarterly PAT in the last 6 quarters on our records; revenue is at a 6-quarter high.

No independent analyst consensus for this print turned up in a web search, so the reading is against our own pre-result preview, which flagged expected revenue of ~₹1,850–1,900 Cr, an EBITDA margin watch of 21–23%, and organic growth of 10%+ as the bar — the actual print clears all three (standalone revenue ₹2,119 Cr, consolidated EBITDA margin 22.9%, revenue growth 21% YoY). Against management's own FY27 guidance from the June 4, 2026 concall — consolidated revenue growth of 12–13% and EBITDA margin improving to 22–22.3% from 20.7% — Q1 is already running ahead of pace on both counts, with margin printing at the top of the full-year target in the very first quarter. Domestic branded formulations grew 13%, roughly matching the guided ~12%. The Krebs Biochemicals amalgamation, board-approved June 26, 2026 with an April 1, 2026 appointed date, remains pending consents and is not yet reflected in these numbers. The ₹6/share dividend (record date August 7) and today's AGM are procedural, not P&L-relevant.